{"personrec":{"StatusID":1,"PersStatus":null,"Status":"Valid","PersID":36192,"PersName":"Dumez, Herlinde","PublicFlag":1,"CheckedFlag":0,"Surname":"Dumez","Firstname":"Herlinde","Initials":"H.","AddressedAs":null,"Function":null,"DateLastModified":{"date":"2023-05-02 10:08:18.393000","timezone_type":1,"timezone":"+00:00"},"PersTitle":null,"PersStatusID":null,"AbstractEnglish":null,"AbstractOtherLang":null,"AbstractLangCode":null,"AbstractLangID":null,"AutID":225793,"ND":"2018-08-08","UD":"2018-08-08"},"loaninfo":null,"pictures":[],"institutes":[{"instituterec":{"OrderNr":1,"Acronym":null,"ENFunction":null,"InsIDtmp":13815,"OrigNameLangCode":"en","OrigNameLangID":15,"FullOrigName":"University Hospitals Leuven","InsID":13815,"Function":null,"BeginDay":null,"BeginMonth":null,"BeginYear":null,"Begindate":"","Enddate":"","PIAdrID":null,"AdrID":159349,"Line1":"Herestraat 49","Line2":"3000 Leuven","Line3":null,"Line4":null,"Phone":null,"GSM":null,"Email":null,"EnvName":"Belgium","EncAddress":"Herestraat 49, 3000 Leuven, Belgium","FullStandardName":"UZ Leuven","DirectorFlag":null,"MarineSciFlag":null,"SpecializedFlag":null},"parent":null,"institutes":null,"references":null,"conferences":null,"datasets":null,"persons":null,"pastpers":null,"subpers":null,"projects":null,"urls":null,"pictures":null,"published":null,"affrefs":null,"collections":null,"thesterms":null,"taxterms":null,"geoterms":null,"thestermsFRIS":null,"nXtins":null,"previns":null,"spcols":null,"resmessage":"no id specified","complete":0,"participantrec":null,"peerrevs":null,"urlmaps":null}],"pastins":[],"projects":[],"datasets":null,"references":{"A1":[{"BRefID":257564,"RR":"<b>Schoffski, P.; Dumez, H.; Ruijter, R.; Miguel-Lillo, B.; Soto-Matos, A.; Alfaro, V.; Giaccone, G.</b> (2011). Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. <i>Cancer Chemother. Pharmacol. 68(6)</i>: 1397-1403. <a href=\"http://dx.doi.org/10.1007/s00280-011-1612-1\" target=\"_blank\">dx.doi.org/10.1007/s00280-011-1612-1</a>","AutID":225793,"MonDate":null,"AnaDate":2011,"PeerRev":1,"outputType":"1_A1","OpenAcc":0},{"BRefID":296108,"RR":"<b>Dumez, H.; Gallardo, E.; Culine, S.; Galceran, J.C.; Schöffski, P.; Droz, J.P.; Extremera, S.; Szyldergemajn, S.; Fléchon, A.</b> (2009). Phase II study of biweekly Plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. <i>Mar. Drugs 7(3)</i>: 451-463. <a href=\"https://dx.doi.org/10.3390/md7030451\" target=\"_blank\">https://dx.doi.org/10.3390/md7030451</a>","AutID":335702,"MonDate":null,"AnaDate":2009,"PeerRev":1,"outputType":"1_A1","OpenAcc":1},{"BRefID":296118,"RR":"<b>Schöffski, P.; Guillem, V.; Garcia, M.; Rivera, F.; Tabernero, J.; Cullell, M.; Lopez-Martin, J.A.; Pollard, P.; Dumez, H.; del Muro, X.; Paz-Ares, L.</b> (2009). Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. <i>Mar. Drugs 7(1)</i>: 57-70. <a href=\"https://dx.doi.org/10.3390/md7010057\" target=\"_blank\">https://dx.doi.org/10.3390/md7010057</a>","AutID":328804,"MonDate":null,"AnaDate":2009,"PeerRev":1,"outputType":"1_A1","OpenAcc":1},{"BRefID":301320,"RR":"<b>Schöffski, P.; Dumez, H.; Wolter, P.; Stefan, C.; Wozniak, A.; Jimeno, J.; Van Oosterom, A.T.</b> (2008). Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. <i>Expert Opinion on Pharmacotherapy 9(9)</i>: 1609-1618. <a href=\"https://dx.doi.org/10.1517/14656566.9.9.1609\" target=\"_blank\">https://dx.doi.org/10.1517/14656566.9.9.1609</a>","AutID":344445,"MonDate":null,"AnaDate":2008,"PeerRev":1,"outputType":"1_A1","OpenAcc":0},{"BRefID":258000,"RR":"<b>Schöffski, P.; Grunwald, V.; Giaccone, G.; Salazar, R.; Majem, M.; Dumez, H.; Casado, E.; de las Heras, B.; Armand, J.</b> (2008). Outcome of three Phase I trials of the marine compound ES-285 (3 hour infusion) in patients with refractory solid tumors. <i>European journal of cancer. Supplement (1990) 6(12)</i>: 56-56. <a href=\"http://dx.doi.org/10.1016/S1359-6349(08)72108-6\" target=\"_blank\">dx.doi.org/10.1016/S1359-6349(08)72108-6</a>","AutID":228302,"MonDate":null,"AnaDate":2008,"PeerRev":1,"outputType":"1_A1","OpenAcc":1}]},"urls":null,"spcols":null,"thesterms":null,"taxterms":null,"pub":1,"newses":{"SesID":89734,"LoginName":"VLIZ2000\\zohrab","LoginID":435,"DD":"2018-08-08"},"updses":{"SesID":89734,"LoginName":"VLIZ2000\\zohrab","LoginID":435,"DD":"2018-08-08"},"urlmaps":[],"resmessage":"no id specified","complete":1}